MedTrace Logo

Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects

NCT00352911 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2010-03-09

Study results available
· View outcomes & findings →

Summary

The objective of the study is to determine whether mifepristone (VGX-410) has anti-HIV-1 activity at doses of either 300 mg or 600 mg per day after oral administration for 14 days at each dose level.

Conditions

  • HIV Infections

Interventions

DRUG

VGX-410 (Mifepristone)

DRUG

Placebo for VGX-410 (Mifepristone)

Sponsors & Collaborators

  • VGX Pharmaceuticals, LLC

    lead INDUSTRY

Principal Investigators

  • Princy Kumar, M.D. · Georgetown University

  • Valerianna Amorosa, MD · Veteran's Hospital of Philadelphia

  • Pablo Tebas, M.D. · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-06-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352911 on ClinicalTrials.gov